The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer : a multicenter phase II trial
© 2024. The Author(s)..
This multicenter, phase II study (NCT03872791) aims to evaluate the efficacy and safety of the anti-PD-L1/CTLA-4 bispecific antibody KN046 combined with nab-paclitaxel in the first-line treatment of patients with metastatic triple-negative breast cancer (TNBC). The primary endpoints included objective response rate (ORR) and duration of response (DoR), and secondary endpoints included progression-free survival (PFS), overall survival (OS) rate, safety, and the correlation of PD-L1 status with clinical efficacy. This trial met pre-specified endpoints. 27 female patients were enrolled sequentially to receive KN046 in two dose levels (3 mg/kg or 5 mg/kg). Among the 25 evaluable patients, the ORR achieved 44.0% (95% CI, 24.4% - 65.1%), and the median DoR was not mature. The median PFS reached 7.33 months (95%CI, 3.68 - 11.07 months), and the median OS was 30.92 months (95%CI, 14.75 - NE months). In PD-L1 positive patients, PFS was 8.61 months (versus 4.73 months) and the 2-year OS rate was 62.5% (versus 57.1%) compared to PD-L1 negative patients. Patients tolerated well the combination therapy. In general, KN046 combined with nab-paclitaxel showed favorable efficacy and survival benefits with tolerable toxicity in the first-line treatment of metastatic TNBC, especially PD-L1 positive, which is worth further investigation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Nature communications - 15(2024), 1 vom: 03. Feb., Seite 1015 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Qiao [VerfasserIn] |
---|
Links: |
---|
Themen: |
130-nm albumin-bound paclitaxel |
---|
Anmerkungen: |
Date Completed 07.02.2024 Date Revised 07.02.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41467-024-45160-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367996707 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367996707 | ||
003 | DE-627 | ||
005 | 20240207232314.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240204s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41467-024-45160-y |2 doi | |
028 | 5 | 2 | |a pubmed24n1283.xml |
035 | |a (DE-627)NLM367996707 | ||
035 | |a (NLM)38310192 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Qiao |e verfasserin |4 aut | |
245 | 1 | 4 | |a The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer |b a multicenter phase II trial |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.02.2024 | ||
500 | |a Date Revised 07.02.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a This multicenter, phase II study (NCT03872791) aims to evaluate the efficacy and safety of the anti-PD-L1/CTLA-4 bispecific antibody KN046 combined with nab-paclitaxel in the first-line treatment of patients with metastatic triple-negative breast cancer (TNBC). The primary endpoints included objective response rate (ORR) and duration of response (DoR), and secondary endpoints included progression-free survival (PFS), overall survival (OS) rate, safety, and the correlation of PD-L1 status with clinical efficacy. This trial met pre-specified endpoints. 27 female patients were enrolled sequentially to receive KN046 in two dose levels (3 mg/kg or 5 mg/kg). Among the 25 evaluable patients, the ORR achieved 44.0% (95% CI, 24.4% - 65.1%), and the median DoR was not mature. The median PFS reached 7.33 months (95%CI, 3.68 - 11.07 months), and the median OS was 30.92 months (95%CI, 14.75 - NE months). In PD-L1 positive patients, PFS was 8.61 months (versus 4.73 months) and the 2-year OS rate was 62.5% (versus 57.1%) compared to PD-L1 negative patients. Patients tolerated well the combination therapy. In general, KN046 combined with nab-paclitaxel showed favorable efficacy and survival benefits with tolerable toxicity in the first-line treatment of metastatic TNBC, especially PD-L1 positive, which is worth further investigation | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Clinical Trial, Phase II | |
650 | 4 | |a Journal Article | |
650 | 7 | |a 130-nm albumin-bound paclitaxel |2 NLM | |
650 | 7 | |a Albumins |2 NLM | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a B7-H1 Antigen |2 NLM | |
650 | 7 | |a CTLA-4 Antigen |2 NLM | |
650 | 7 | |a Paclitaxel |2 NLM | |
650 | 7 | |a P88XT4IS4D |2 NLM | |
700 | 1 | |a Liu, Jiaxuan |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Qingyuan |e verfasserin |4 aut | |
700 | 1 | |a Ouyang, Quchang |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yang |e verfasserin |4 aut | |
700 | 1 | |a Liu, Qiang |e verfasserin |4 aut | |
700 | 1 | |a Sun, Tao |e verfasserin |4 aut | |
700 | 1 | |a Ye, Feng |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Baochun |e verfasserin |4 aut | |
700 | 1 | |a Xia, Summer |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Bangyong |e verfasserin |4 aut | |
700 | 1 | |a Xu, Binghe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 03. Feb., Seite 1015 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:03 |g month:02 |g pages:1015 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-45160-y |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2024 |e 1 |b 03 |c 02 |h 1015 |